Episode
Tesamorelin: The Age-less Pulse of Growth Hormone | Age-Less Top 20 Peptides
- Published
- Jun 3, 2026
- Duration seconds
- 1514
- Processing state
not_requested- Canonical source
- https://rss.com/podcasts/the-science-of-age-less-living/2883374
Actions
POST https://stenobird.com/v1/public/podcasts/the-science-of-age-less-living-7235688/episodes/tesamorelin-the-age-less-pulse-of-growth-hormone-age-less-top-20-peptides/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-science-of-age-less-living-7235688/tesamorelin-the-age-less-pulse-of-growth-hormone-age-less-top-20-peptides.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
In the mid-1990s, antiretroviral therapy was transforming HIV from a death sentence into a chronic condition — and creating an unexpected syndrome in its wake. Patients on the new combinations were developing visceral fat accumulation, peripheral fat loss, dyslipidaemia, and a measurably blunted growth hormone rhythm. A small Canadian biotech in Montréal saw the lever. Native GHRH had a half-life of seven minutes, cleaved almost instantly by an enzyme called DPP-IV. Their structural innovation — adding a single trans-3-hexenoic acid group to the N-terminus — blocked the cleavage site, extended the half-life to twenty-six minutes, and made an entire pharmacology clinically viable. That compound is Tesamorelin, and in 2010 it became one of the very few synthetic peptides ever to clear the full FDA approval pathway. In this episode, Dr. Ethan walks through the molecule properly. The forty-four amino acid sequence, the structural modification that makes it work, and the mechanism that distinguishes it from every other growth hormone strategy: Tesamorelin doesn't introduce GH, it activates the body's own pituitary to release GH in its natural pulsatile pattern, preserving somatostatin feedback and the physiological rhythm that exogenous rhGH abolishes. The episode follows the cascade from GHRH receptor binding through cAMP and PKA activation to pulsatile GH release, hepatic IGF-1 production, and the anabolic and lipolytic effects downstream. Then the human evidence — and this is where Tesamorelin sits in a category of its own. Two pivotal Phase III trials, fifteen years of post-marketing data, and a defined safety profile in HIV-associated lipodystrophy. Emerging Phase II data in MASLD showing meaningful reductions in hepatic fat. Exploratory work in cognitive function, sar…